Solute carrier (SLC) transporters play important roles in regulating the movement of small molecules and ions across cellular membranes. In mammals, they play an important role in regulating the uptake of nutrients and vitamins from the diet, and in controlling the distribution of their metabolic intermediates within the cell. Several SLC families also play an important role in drug transport and strategies are being developed to hijack SLC transporters to control and regulate drug transport within the body. Through the addition of amino acid and peptide moieties several novel antiviral and anticancer agents have been developed that hijack the proton-coupled oligopeptide transporters, PepT1 (SCL15A1) and PepT2 (SLC15A2), for improved intestinal absorption and renal retention in the body. A major goal is to understand the rationale behind these successes and expand the library of prodrug molecules that utilise SLC transporters. Recent co-crystal structures of prokaryotic homologues of the human PepT1 and PepT2 transporters have shed important new insights into the mechanism of prodrug recognition. Here, I will review recent developments in our understanding of ligand recognition and binding promiscuity within the SLC15 family, and discuss current models for prodrug recognition.

Introduction

Solute carrier (SLC) transporters are important determinants of drug pharmacokinetics and are increasingly being identified as important therapeutic targets in their own right [1,2]. Poor oral bioavailability is one of the leading causes of failure in preclinical and clinical drug development and is viewed as a major challenge in the pharmaceutical and biotechnology industry [3]. One approach to address this challenge has been the development of prodrugs that target the intestinal peptide transporter, PepT1 (SLC15A1), which is highly expressed in the brush border membrane of the small intestine [4,5] (Figure 1A). The central idea is to modify existing drug molecules so that they resemble the physiological peptides found in the small intestine and thereby co-opt the peptide transporters into driving drug their uptake into the body. Modifying drugs to improve their pharmacokinetic properties results in so-called prodrugs, which are generally bioreversible derivatives of the parent drug molecules that undergo an enzymatic or chemical transformation in vivo to release the active parent drug [6]. Over the past 10 years, significant effort has been made in the design of novel prodrug molecules with improved pharmacokinetic profiles [7,8]. One successful approach has been to use amino acids as promoieties, as these confer several advantages on the parent compound, including increased water solubility and the targeting of intestinal SLC transporters for oral drug delivery [9].

Peptide transporters are targeted to improve drug transport into the body.

Figure 1.
Peptide transporters are targeted to improve drug transport into the body.

(A) The addition of an amino acid to a drug molecule results in the generation of a prodrug (1) that is able to utilise the intestinal proton-coupled peptide transporter, PepT1, for active transport across the cell membrane and into the body (2). Once in the cytoplasm, the prodrug is acted upon by enzymes that cleave the linker bond (3) and release the parent drug (4). (B) Crystal structure of a POT family transporter showing the N- and C-terminal bundles, coloured green and blue, respectively. The central peptide binding site is shown in surface electrostatics (blue positive; red negative). The transporter is shown in the inward-open conformation, with the peptide binding site closed to the extracellular side of the membrane and open to the cytoplasm. Two gates control access to the binding site, which alternately open and close in response to peptide and proton binding. (C) The peptide binding site contains several specificity pockets that recognise peptides and their associated side chains.

Figure 1.
Peptide transporters are targeted to improve drug transport into the body.

(A) The addition of an amino acid to a drug molecule results in the generation of a prodrug (1) that is able to utilise the intestinal proton-coupled peptide transporter, PepT1, for active transport across the cell membrane and into the body (2). Once in the cytoplasm, the prodrug is acted upon by enzymes that cleave the linker bond (3) and release the parent drug (4). (B) Crystal structure of a POT family transporter showing the N- and C-terminal bundles, coloured green and blue, respectively. The central peptide binding site is shown in surface electrostatics (blue positive; red negative). The transporter is shown in the inward-open conformation, with the peptide binding site closed to the extracellular side of the membrane and open to the cytoplasm. Two gates control access to the binding site, which alternately open and close in response to peptide and proton binding. (C) The peptide binding site contains several specificity pockets that recognise peptides and their associated side chains.

However, targeting specific SLC transporters for carrier mediated uptake is still a major challenge and made more difficult due to the absence of structural and biochemical information on many SLC transporters [10]. Two members of the SLC15 family of proton-coupled peptide transporters, PepT1 (SLC15A1) and PepT2 (SLC15A2) exhibit remarkable ligand promiscuity, and are known to transport many different drug molecules, including angiotensin-converting enzyme inhibitors, beta-lactam antibiotics, an N-methyl-d-aspartate receptor antagonist PD-15874 and 5-aminolevulinic acid, currently being evaluated as a treatment for bladder and oesophageal cancer [11–13]. In a quirk of physiological fate, these transporters perform a virtuous cycle if targeted correctly, with PepT1 being expressed in the small intestine and so able to effectively transport drugs into the blood stream, and PepT2 expressed in the kidney nephrons, acting to retain the drugs and exclude their excretion in the urine. Additionally, PepT2 is also expressed in the problematic blood-brain barrier, where it functions to control peptide transport into the central nervous system [14]. It is perhaps not surprising, therefore, that prodrugs targeting both PepT1 and PepT2 show favourable absorption and retention profiles in animal models of drug disposition and are being actively pursued as valid targets for improving biopharmaceutical and pharmacokinetic profiles in humans [15–17].

A major breakthrough in carrier mediated prodrug development was the introduction of the antiviral valacyclovir in 1995, marketed under the trade names Valtrex and Zelitrex. Valacyclovir is a prodrug derivative of the antiviral agent acyclovir, which is used in the treatment of herpes virus as well as in prophylaxis against the acquisition of infection and in the suppression of latent disease [18]. This was soon followed by another prodrug, valganciclovir in 2001, which is used to treat cytomegalovirus infections in patients with HIV/AIDS or following organ transplant [19] and marketed under the trade name Valcyte. The oral bioavailability of both valacyclovir and valganciclovir improved to >50% for the prodrug derivative, which was attributed to its recognition and transport by intestinal peptide transporter PepT1 [20–24]. Intestinal transporters are often targeted for prodrug transport, as they function to rapidly transport a variety of chemical different molecules into the blood stream from the diet [8]. Within the repertoire of intestinal SLC transporters, PepT1 stands out as displaying the most extreme promiscuity [25]. This characteristic, coupled with the similarity of both amino acid side chains to functional groups of drug molecules and the size of di- and tri-peptides to small molecule therapeutics [11], has resulted in PepT1 being a major focus of prodrug design strategies [26–28]. However, the lack of a high-resolution 3D structure and associated pharmacophore model for drug binding has hampered progress [29]. Recently, however, three co-crystal structures have been reported that show two different bacterial peptide transporters in complex with two prodrug molecules and the peptide-based photodynamic therapy agent, 5-aminolevulinc acid [30,31]. Bacterial peptide transporters have proven to be valid model systems with which to understand the molecular basis of peptide recognition within the human transporters [32–34]. In the context of several previous structural studies showing how this family of transporters recognise and transport physiological peptides across the membrane, a picture now starts to emerge of a unified binding mechanism that will likely form the basis for developing a more accurate pharmacophore model for drug recognition and transport within the human SLC15 family [35].

SLC15 transporters belong to the larger POT family of proton-coupled peptide transporters

PepT1 and PepT2 belong to the much larger POT or PTR family of proton-coupled oligopeptide transporters, with homologues found in all domains of life except the archaea [36,37]. POT family transporters belong to the major facilitator superfamily (MFS) of secondary active transporters, and use the proton electrochemical gradient to drive the concentrative uptake of di- and tri-peptides into the cell [38]. Structurally they contain 12 transmembrane (TM) spanning alpha helices, which pack together into two six-helix bundles in the membrane [39] (Figure 1B). A central ligand-binding site is located within the centre of the molecule, flanked on either side by the two six-helix bundles. Access to the central binding site is controlled by two gates at the extracellular and intracellular end of the central cavity [40]. The gates themselves are made up of four pairs of helices, two from each of the six-helix bundles [41]. Several studies have determined that the gates are opened and closed in response to both peptide and proton binding, which appear to regulate the formation and breakage of conserved salt bridge interactions made between the gating helices [42–45]. A remarkable feature of POT family transporters is the promiscuity of the binding site, with the upper estimate for the number of di and tri-peptide ligands that can be recognised and transported in the several thousand [46]. Here structural studies have built on previous electrophysiological and biochemical transport studies to reveal a highly charged binding site that exhibits a pronounced dipolar character (Figure 1C) [4,40]. Crystal structures and biochemical assays have further revealed a general model for how peptides are recognised [34,47–49], with important roles for conserved hydrophobic and polar pockets. In brief, the amino and carboxy termini of the peptides are recognised by conserved acidic and basic side chains within the binding site, with specificity provided by pockets with varying degrees of polar and hydrophobic character, which accommodate the different side chains. Additionally, several POT transporters also appear to recognise peptides in different orientations, with larger tri-peptides accommodated in vertical orientations and smaller di-peptides being held in a more horizontal orientation [47,50]. Interested readers are directed to towards recent reviews that discuss these results and the mechanisms for proton-coupled peptide transport [33,38]. Here, we wish to focus instead on how two recent structures of prodrug complexes have expanded our understanding of drug recognition and pharmacophore development.

Rationalising prodrug recognition

Recently two crystal structures of different POT family transporters in complex with the antiviral prodrugs valacyclovir and valganciclovir were reported [30,31]. These two prodrugs are very similar, except for the presence of a methoxy group in the ganciclovir parent molecule and both are current prescribed to treat cytomegalovirus infections. The crystal structures revealed the two molecules in the central peptide binding site, but interestingly in different orientations (Figure 2A). In the valacyclovir complex, which was captured in the POT family transporter from Staphylococcus hominis, PepTSh, the prodrug molecule is seen with the valine moiety orientated towards the extracellular gate, with the amino terminus making both a hydrogen bond and salt bridge interaction with Asn347 and Glu418 (PDB: 6GZ9) (Figure 2B). The latter residue being an important component of the proton coupling mechanism [43]. The ester group, which connects the valine amino acid to the parent drug molecule, interacts via another hydrogen bond to one of two conserved tyrosine side chains, Tyr41, which was identified as playing an important role in ligand specificity [43]. Valacyclovir also contains an ether bond, which belongs to the parent drug molecule, which also interacts with a conserved tyrosine, Tyr79, again identified as playing an important role in ligand specificity within the wider SLC15/POT family [38]. Of particular interest is how the parent drug molecule is accommodated. As mentioned, in the peptide complexes we have observed that large side chains are accommodated in specificity pockets. Indeed, we suggested a similar situation may occur for prodrug molecules, with the drug component being accommodated within the hydrophobic pocket we observed previously [51]. However, in this structure, the acyclovir component is accommodated through a pi–pi stacking interaction with another tyrosine, Tyr163. Interestingly this tyrosine forms part of the PTR2_2 (FYxxINxG) motif on TM4 in PepTSh, which forms part of the intracellular gate in POT family transporters. The function of the PTR2_2 motif is currently unclear, but it is highly conserved in the bacterial POT family transporters [36] and the equivalent tyrosine in rabbit PepT1 is essential for transport [52], suggesting it may play a similarly important role in drug transport in the human proteins.

Comparison of the crystal structure of POT transporters in complex with prodrugs valacyclovir and valganciclovir.

Figure 2.
Comparison of the crystal structure of POT transporters in complex with prodrugs valacyclovir and valganciclovir.

(A) Overlay of the two prodrugs in their respective transporters. Valacyclovir (yellow) was captured in PepTSh (blue), while valganciclovir (green) was captured in DtpA (brown). Amino acid positions are labelled for PepTSh. (B) View of the binding site for valacyclovir in PepTSh (PDB: 6GZ9). (C) View of the binding site for valganciclovir in DtpA (PDB: 6GS4). (D) Schematic view of the binding interactions for valacyclovir. (E) Schematic view of the binding interactions for valganciclovir. Hydrogen bonds are shown in dashed red lines, distances shown are in Ångstroms.

Figure 2.
Comparison of the crystal structure of POT transporters in complex with prodrugs valacyclovir and valganciclovir.

(A) Overlay of the two prodrugs in their respective transporters. Valacyclovir (yellow) was captured in PepTSh (blue), while valganciclovir (green) was captured in DtpA (brown). Amino acid positions are labelled for PepTSh. (B) View of the binding site for valacyclovir in PepTSh (PDB: 6GZ9). (C) View of the binding site for valganciclovir in DtpA (PDB: 6GS4). (D) Schematic view of the binding interactions for valacyclovir. (E) Schematic view of the binding interactions for valganciclovir. Hydrogen bonds are shown in dashed red lines, distances shown are in Ångstroms.

The second structure of a prodrug complex was reported DtpA, from Escherichia coli, in complex with valganciclovir (PDB: 6GS4) [31]. Although very similar to valacyclovir, the valganciclovir molecule sits in a different orientation, flipped almost 180° relative to valacyclovir (Figure 2A,C). In this structure, it is the nucleoside analogue that interacts with the conserved glutamate on TM10, Glu396 in this protein, via amid nitrogen N16 (Figure 2E). The conserved asparagine on TM 8, Asn325, that was observed interacting with the amino group in valacyclovir, is not interacting with the prodrug in DtpA, instead this side chain makes an interaction to Glu396. Similarly, to the valacyclovir structure, the carbonyl group on the nucleoside moiety interacts with another conserved asparagine, Asn 160 on TM4. However, in the PepTSh structure, the asparagine is different, and on TM10. Also dissimilar to the valacyclovir structure, the hydrogen bond interactions with valganciclovir cease at the additional methoxy group of the parent drug, which interacts with a conserved tyrosine on TM1, Tyr38. The remaining valine amino acid is accommodated in a hydrophobic pocket formed by Try71, Phe289, Ily399 and Leu402.

What could account for this difference in binding orientation? Interestingly in the DtpA structure, the region around TM10 is structurally very different when compared with PepTSh (Figure 3). In DtpA the region towards the cytoplasmic end of the helix forms a disordered region, before reforming the helix and connecting into TM11. In comparison, in PepTSh TM10 forms a single helical structure, with no similar disordered loop. Given the importance that TM10 and 11 play in regulating access to the central peptide binding site during transport [41], it is highly likely this structural difference will impact how these proteins recognise peptides and prodrugs. Indeed, substrate preferences between di- and tri-peptides are much more pronounced in bacterial members of the POT family, with reports that the E. coli YjdL transporter preferring di-peptides over larger tri-peptides for example [53]. It is possible that similar differences in helix structure within the different POT family transporters have resulted in altered substrate preferences and peptide binding orientations. Unfortunately, it appears that sequence alone is insufficient to determine whether this structural characteristic is present in the mammalian transporters, as the sequence of the proteins in this region is very similar between DtpA and PepTSh.

Helix 10 in DtpA adopts an usual conformation compared with PepTSh.

Figure 3.
Helix 10 in DtpA adopts an usual conformation compared with PepTSh.

Structural comparison of the TM10 and TM11 helices in DtpA and PepTSh. Helix 10 in DtpA adopts an unwound conformation towards the cytoplasmic end of the helix, resulting in a pronounced displacement of the backbone relative to PepTSh. A sequence alignment of DtpA with PepTSh and other bacterial POT family transporters is shown, revealing that the structural difference cannot be predicted from the primary structure.

Figure 3.
Helix 10 in DtpA adopts an usual conformation compared with PepTSh.

Structural comparison of the TM10 and TM11 helices in DtpA and PepTSh. Helix 10 in DtpA adopts an unwound conformation towards the cytoplasmic end of the helix, resulting in a pronounced displacement of the backbone relative to PepTSh. A sequence alignment of DtpA with PepTSh and other bacterial POT family transporters is shown, revealing that the structural difference cannot be predicted from the primary structure.

An emerging pharmacophore and peptide binding model

A key aim of research into the POT family of peptide transporters is to gain a working understanding of how these proteins recognise and transport drug molecules across the cell membrane. An accurate pharmacophore model, supported by cell and biochemical transport assays has been a key goal of the transport field [35]. After several years of effort from multiple researchers around the world, we now have a selection of high-quality crystal structures of POT family transporters in complex with different physiological peptide ligands (Table 1). These include six complexes with di-peptides and three with tri-peptides. Given the reasonable sequence identity between the mammalian and bacterial proteins, we can use these structures to gain important insights into how the mammalian peptide transporters might recognise peptides and drug molecules in the human body. Fortuitously all of the current crystal structures have been captured in essentially the same inward-facing conformation, with the binding site open to the cytoplasm and sealed on the outside of the cell. This enables us to superimpose the structures and observe any similarities in how these different peptide transporters interact with their ligands. Indeed, we observe several commonalities in the way these proteins recognise their peptide ligands and the prodrug valacyclovir (Figure 4A,B). It appears the amino terminus of the peptides and valine moiety of the prodrug interact with a conserved asparagine on TM10, Asn347. Interestingly, the carboxy termini of the peptides also cluster in one region of the binding site, interacting with the two conserved tyrosines on TM1 and 2, Tyr41 and 79, respectively. In the valacyclovir complex, it is these tyrosines that interact with the ester and ether bonds of the prodrug (Figure 2B,D). Tyrosines are well known to play important roles in promiscuous binding sites in proteins, and are often concentrated in the CDR3 loop of antibodies [54]. It is likely that they play a similar role in increasing the repertoire of interactions available within the binding site of POT family transporters. Supporting this hypothesis, we observe the acyclovir drug group, which is a nucleoside analogue, accommodated through a pi–pi stacking interacting with another tyrosine, Tyr163 on TM4. The last common interaction point we observe is with the carbonyl group, which makes a conserved interaction with Asn167, also on TM4.

Valacyclovir adopts a similar binding position to physiological peptide ligands.

Figure 4.
Valacyclovir adopts a similar binding position to physiological peptide ligands.

(A) Structural overlay of the valacyclovir structure onto PepTSt (4D2B) and in complex with peptides Ala-Phe (PDB:4D2C), Ala-Gln (5OXK), Asp-Glu (5OXM), and tri-alanine (PDB:4D2D). Common points of contact are highlighted. (B) View rotated 90° relative to (A), showing the involvement of the PTR2_2 tyrosine.

Figure 4.
Valacyclovir adopts a similar binding position to physiological peptide ligands.

(A) Structural overlay of the valacyclovir structure onto PepTSt (4D2B) and in complex with peptides Ala-Phe (PDB:4D2C), Ala-Gln (5OXK), Asp-Glu (5OXM), and tri-alanine (PDB:4D2D). Common points of contact are highlighted. (B) View rotated 90° relative to (A), showing the involvement of the PTR2_2 tyrosine.

Table 1.
Crystal structures of all currently reported POT family peptide transporters
POT transporterLigandConformationPDBLiterature
PepTSo2 (Shewanella oneidensis
 apo Inward-open 2XUT Newstead et al. [40
 apo Occluded state 4UVM Fowler et al. [41
 Alafosfalin Inward-open 4LEP Guettou et al. [56
 Ala-Tyr Inward-open 4TPH Guettou et al. [34
 Ala-Ala-Ala Inward-open 4TPJ 
 Ala-Tyr-Ala Inward-open 4TPG 
 apo Inward-open 6JI1 Nagamara et al. [57
PepTSt (Streptococcus thermophilus
 apo Inward-open 4APS Solcan et al. [43
 apo Inward-open 4XNJ Huang et al. [58
 Ala-Phe Inward-open 4D2C Lyons et al. [47
 Ala-Ala-Ala Inward-open 4D2D 
 Ala-Phe Inward-open 5D58 Huang et al. [59
 apo Inward-open 5OXO Martinez-Molledo et al. [49
 apo — PO4 bound Occluded state 5OXP 
 Ala-Leu Inward-open 5OXL 
 Ala-Gln Inward-open 5OXK 
 Asp-Glu Inward-open 5OXM 
 Phe-Ala Inward-open 5OXN 
 Phe-Ala-Gln Inward-open 6GHJ Martinez-Molledo et al. [49
 HEPES Inward-open 6EIA  
PepTSh (Staphylococcus hominis
 Cys-Gly-3M3SH Inward-open 6EXS Minhas et al. [50
 Valacyclovir Inward-open 6GZ9 Minhas and Newstead [30
 5-aminolevulinic acid Inward-open 6HZP 
GkPOT (Geobacillus kaustophilus
 apo Inward-open 4IKV Doki et al. [48
 apo — E310Q Inward-open 4IKX 
 apo — E310Q SO4 bound Inward-open 4IKY 
 SO4 Inward-open 4IKW 
 Alafosfalin Inward-open 4IKZ 
DtpA (Escherichia coli
 Valganciclovir Inward-open 6GS4 Ural-Blimke et al. [31
 MES Inward-open 6GS1 
 Glycine Inward-open 6GS7 
YbgH (Escherichia coli
 apo Inward-open 4Q65 Zhao et al. [60
PepT (Yersinia enterocolitica
 apo Inward-open 4W6V Boggavarapu et al. [61
PepTXc (Xanthomonas campestris
 auto-inhibited Inward-open 6EI3 Parker et al. [42
POT transporterLigandConformationPDBLiterature
PepTSo2 (Shewanella oneidensis
 apo Inward-open 2XUT Newstead et al. [40
 apo Occluded state 4UVM Fowler et al. [41
 Alafosfalin Inward-open 4LEP Guettou et al. [56
 Ala-Tyr Inward-open 4TPH Guettou et al. [34
 Ala-Ala-Ala Inward-open 4TPJ 
 Ala-Tyr-Ala Inward-open 4TPG 
 apo Inward-open 6JI1 Nagamara et al. [57
PepTSt (Streptococcus thermophilus
 apo Inward-open 4APS Solcan et al. [43
 apo Inward-open 4XNJ Huang et al. [58
 Ala-Phe Inward-open 4D2C Lyons et al. [47
 Ala-Ala-Ala Inward-open 4D2D 
 Ala-Phe Inward-open 5D58 Huang et al. [59
 apo Inward-open 5OXO Martinez-Molledo et al. [49
 apo — PO4 bound Occluded state 5OXP 
 Ala-Leu Inward-open 5OXL 
 Ala-Gln Inward-open 5OXK 
 Asp-Glu Inward-open 5OXM 
 Phe-Ala Inward-open 5OXN 
 Phe-Ala-Gln Inward-open 6GHJ Martinez-Molledo et al. [49
 HEPES Inward-open 6EIA  
PepTSh (Staphylococcus hominis
 Cys-Gly-3M3SH Inward-open 6EXS Minhas et al. [50
 Valacyclovir Inward-open 6GZ9 Minhas and Newstead [30
 5-aminolevulinic acid Inward-open 6HZP 
GkPOT (Geobacillus kaustophilus
 apo Inward-open 4IKV Doki et al. [48
 apo — E310Q Inward-open 4IKX 
 apo — E310Q SO4 bound Inward-open 4IKY 
 SO4 Inward-open 4IKW 
 Alafosfalin Inward-open 4IKZ 
DtpA (Escherichia coli
 Valganciclovir Inward-open 6GS4 Ural-Blimke et al. [31
 MES Inward-open 6GS1 
 Glycine Inward-open 6GS7 
YbgH (Escherichia coli
 apo Inward-open 4Q65 Zhao et al. [60
PepT (Yersinia enterocolitica
 apo Inward-open 4W6V Boggavarapu et al. [61
PepTXc (Xanthomonas campestris
 auto-inhibited Inward-open 6EI3 Parker et al. [42

Taken together, we propose an initial binding model for how SLC15 family transporters interact with amino acid-based prodrug molecules (Figure 4C,D). Based on the crystal structures of POT family transporters, we proposed that peptides interact primarily through their amino and carboxy termini, which make salt bridge interactions to the conserved glutamate on TM10 and arginine on TM1, respectively. Our valacyclovir structure reveals that the amino terminus of the valine moiety of the prodrug does indeed interact with the conserved glutamate, however, we did not observe an interaction with the arginine on TM1, possibly due to the absence of a carboxy group in the prodrug, or maybe steric restrictions resulting from accommodating the larger drug group in the binding site. However, we did observe interactions conserved interactions with a tyrosine on TM1, which recognises the peptide bond in peptides and the ester group in valacyclovir, and an asparagine on TM4, which recognises the carbonyl group of the peptide bond in peptides and the equivalent carbonyl group in valacyclovir. In many ways, this model supports earlier suggestions that addition of the amino acid to drug molecules enables the prodrug to dock into the binding site, whereupon the promiscuous nature of the site, generated from the increased concentration of tyrosine side chains, accommodates the remaining drug group [51]. This model also sits in good agreement with an earlier binding model generated for the rabbit peptide transporter, PepT1, which also noted the importance of the interactions to the amino group of the peptide to the overall affinity of the ligands for the transporter [4,55].

This model, however, is difficult to reconcile with the valganciclovir structure obtained for DtpA, which as discussed above adopts a very different orientation in this transporter. However, we have seen in other POT family transporters that part of the mechanism by which these proteins accommodate such a large repertoire of ligands is through the use of multiple binding modes within the same site [47,49]. It may well be the case that slight changes to the drug molecules enable a different binding orientation, or that changes in the structure of the binding site, as observed in TM10 in DtpA, enable different sets of ligands to be accommodated. It should be remembered that peptide transporters function to transport peptides en masse into the cell; they have evolved as bulk carriers, not selective uptake systems. Specificity has been sacrificed for efficiency and promiscuity. The different binding orientations observed between valacyclovir and valganciclovir may be indicating that multiple pharmacophore models exist for PepT1 and PepT2.

Future questions

The era of precision medicine is rapidly approaching, with advances in genomics and metabolomics enabling a much greater understanding of how human beings metabolise and respond to different drug regimens. Understanding the role and regulation of SLC transporters in the human body is a major plank of this worldwide endeavour. The ability to co-opt intestinal and renal drug transporters to improve drug absorption and retention has been a success to date with antivirals and antineoplastic agents, but is ultimately hampered by a lack of high-resolution structural, biochemical and biophysical data on how these systems interact with drug molecules. The structures presented here sound the starting gun towards a unified pharmacophore model to understand how best to target PepT1 and PepT2 for improved drug delivery and reduced cytotoxicity in the human body.

Perspectives

  • SLC proteins are responsible for transporting drugs into and throughout the human body; they play a major role in drug pharmacokinetics.

  • The SLC15 family of peptide transporters have been targeted to improve the oral bioavailability and renal retention of antiviral prodrugs valacyclovir and valganciclovir.

  • Recent crystal structures of bacterial SLC15 homologues in complex with antiviral prodrugs have revealed how these two drug molecules are recognised, paving the way for more targeted prodrug design.

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Abbreviations

     
  • MFS

    major facilitator superfamily

  •  
  • SLC

    solute carrier

  •  
  • TM

    transmembrane

Open Access

Open access for this article was enabled by the participation of University of Oxford in an all-inclusive Read & Publish pilot with Portland Press and the Biochemical Society under a transformative agreement with JISC.

References

References
1
Giacomini
,
K.M.
,
Huang
,
S.-M.
,
Tweedie
,
D.J.
,
Benet
,
L.Z.
,
Brouwer
,
K.L.R.
,
Chu
,
X.
et al (
2010
)
Membrane transporters in drug development
.
Nat. Rev. Drug Discov.
9
,
215
236
2
Lin
,
L.
,
Yee
,
S.W.
,
Kim
,
R.B.
and
Giacomini
,
K.M.
(
2015
)
SLC transporters as therapeutic targets: emerging opportunities
.
Nat. Rev. Drug Discov.
14
,
543
560
3
Thomas
,
V.H.
,
Bhattachar
,
S.
,
Hitchingham
,
L.
,
Zocharski
,
P.
,
Naath
,
M.
,
Surendran
,
N.
et al (
2006
)
The road map to oral bioavailability: an industrial perspective
.
Expert Opin. Drug Metab. Toxicol.
2
,
591
608
4
Bailey
,
P.
,
Boyd
,
C.
,
Bronk
,
J.
,
Collier
,
I.
,
Meredith
,
D.
,
Morgan
,
K.
et al (
2000
)
How to make drugs orally active: a substrate template for peptide transporter PepT1
.
Angew. Chem.
39
,
505
508
5
Rubio-Aliaga
,
I.
and
Daniel
,
H.
(
2002
)
Mammalian peptide transporters as targets for drug delivery
.
Trends Pharmacol. Sci.
23
,
434
440
6
Jornada
,
D.H.
,
dos Santos Fernandes
,
G.F.
,
Chiba
,
D.E.
,
de Melo
,
T.R.
,
dos Santos
,
J.L.
and
Chung
,
M.C.
(
2015
)
The prodrug approach: a successful tool for improving drug solubility
.
Molecules
21
,
42
7
Murakami
,
T.
(
2016
)
A minireview: usefulness of transporter-targeted prodrugs in enhancing membrane permeability
.
J. Pharm. Sci.
105
,
2515
2526
8
Rautio
,
J.
,
Meanwell
,
N.A.
,
Di
,
L.
and
Hageman
,
M.J.
(
2018
)
The expanding role of prodrugs in contemporary drug design and development
.
Nat. Rev. Drug Discov.
17
,
559
587
9
Vig
,
B.S.
,
Huttunen
,
K.M.
,
Laine
,
K.
and
Rautio
,
J.
(
2013
)
Amino acids as promoieties in prodrug design and development
.
Adv. Drug Deliv. Rev.
65
,
1370
1385
10
Cesar-Razquin
,
A.
,
Snijder
,
B.
,
Frappier-Brinton
,
T.
,
Isserlin
,
R.
,
Gyimesi
,
G.
,
Bai
,
X.
et al (
2015
)
A call for systematic research on solute carriers
.
Cell
162
,
478
487
11
Brandsch
,
M.
(
2013
)
Drug transport via the intestinal peptide transporter PepT1
.
Curr. Opin. Pharmacol.
13
,
881
887
12
Qumseya
,
B.J.
,
David
,
W.
and
Wolfsen
,
H.C.
(
2013
)
Photodynamic therapy for Barrett's esophagus and esophageal carcinoma
.
Clin. Endosc.
46
,
30
37
13
Anderson
,
C.M.H.
,
Jevons
,
M.
,
Thangaraju
,
M.
,
Edwards
,
N.
,
Conlon
,
N.J.
,
Woods
,
S.
et al (
2010
)
Transport of the photodynamic therapy agent 5-aminolevulinic acid by distinct H+-coupled nutrient carriers coexpressed in the small intestine
.
J. Pharmacol. Exp. Ther.
332
,
220
228
14
Sala-Rabanal
,
M.
,
Loo
,
D.D.F.
,
Hirayama
,
B.A.
and
Wright
,
E.M.
(
2008
)
Molecular mechanism of dipeptide and drug transport by the human renal H+/oligopeptide cotransporter hPEPT2
.
Am. J. Physiol. Ren. Physiol.
294
,
F1422
F1432
15
Zaïr
,
Z.M.
,
Eloranta
,
J.J.
,
Stieger
,
B.
and
Kullak-Ublick
,
G.A.
(
2008
)
Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney
.
Pharmacogenomics
9
,
597
624
16
Brandsch
,
M.
,
Knütter
,
I.
and
Bosse-Doenecke
,
E.
(
2008
)
Pharmaceutical and pharmacological importance of peptide transporters
.
J. Pharm. Pharmacol.
60
,
543
585
17
Terada
,
T.
and
Inui
,
K.-I.
(
2004
)
Peptide transporters: structure, function, regulation and application for drug delivery
.
Curr. Drug Metab.
5
,
85
94
18
Perry
,
C.M.
and
Faulds
,
D.
(
1996
)
Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections
.
Drugs
52
,
754
772
19
Eid
,
A.J.
and
Razonable
,
R.R.
(
2010
)
New developments in the management of cytomegalovirus infection after solid organ transplantation
.
Drugs
70
,
965
981
20
Yang
,
B.
and
Smith
,
D.
(
2013
)
Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice
.
Drug Metab. Dispos
41
,
608
614
21
Sawada
,
K.
,
Terada
,
T.
,
Saito
,
H.
,
Hashimoto
,
Y.
and
Inui
,
K.I.
(
1999
)
Recognition of L-amino acid ester compounds by rat peptide transporters PEPT1 and PEPT2
.
J. Pharmacol. Exp. Ther.
291
,
705
709
PMID:
[PubMed]
22
Ganapathy
,
M.E.
,
Huang
,
W.
,
Wang
,
H.
,
Ganapathy
,
V.
and
Leibach
,
F.H.
(
1998
)
Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2
.
Biochem. Biophys. Res. Commun.
246
,
470
475
23
Balimane
,
P.V.
,
Tamai
,
I.
,
Guo
,
A.
,
Nakanishi
,
T.
,
Kitada
,
H.
,
Leibach
,
F.H.
et al (
1998
)
Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir
.
Biochem. Biophys. Res. Commun.
250
,
246
251
24
Sugawara
,
M.
,
Huang
,
W.
,
Fei
,
Y.J.
,
Leibach
,
F.H.
,
Ganapathy
,
V.
and
Ganapathy
,
M.E.
(
2000
)
Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2
.
J. Pharm. Sci.
89
,
781
789
25
Ito
,
K.
,
Hikida
,
A.
,
Kawai
,
S.
,
Lan
,
V.T.
,
Motoyama
,
T.
,
Kitagawa
,
S.
et al (
2013
)
Analysing the substrate multispecificity of a proton-coupled oligopeptide transporter using a dipeptide library
.
Nat. Commun.
4
,
2502
26
Incecayir
,
T.
,
Sun
,
J.
,
Tsume
,
Y.
,
Xu
,
H.
,
Gose
,
T.
,
Nakanishi
,
T.
et al (
2016
)
Carrier-mediated prodrug uptake to improve the oral bioavailability of polar drugs: an application to an oseltamivir analogue
.
J. Pharm. Sci.
105
,
925
934
27
Gupta
,
V.
,
Gupta
,
S.
,
Sun
,
D.
,
Dahan
,
J.
,
Tsume
,
A.
,
Hilfinger
,
Y.
et al (
2011
)
Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach
.
Mol. Pharm.
8
,
2358
2367
28
Song
,
X.
,
Lorenzi
,
P.L.
,
Landowski
,
C.P.
,
Vig
,
B.S.
,
Hilfinger
,
J.M.
and
Amidon
,
G.L.
(
2005
)
Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport
.
Mol. Pharm.
2
,
157
167
29
Garibsingh
,
R.A.
and
Schlessinger
,
A.
(
2019
)
Advances and challenges in rational drug design for SLCs
.
Trends Pharmacol. Sci.
40
,
790
800
30
Minhas
,
G.S.
and
Newstead
,
S.
(
2019
)
Structural basis for prodrug recognition by the SLC15 family of proton-coupled peptide transporters
.
Proc. Natl. Acad. Sci. U.S.A.
116
,
804
809
31
Ural-Blimke
,
Y.
,
Flayhan
,
A.
,
Strauss
,
J.
,
Rantos
,
V.
,
Bartels
,
K.
,
Nielsen
,
R.
et al (
2019
)
Structure of prototypic peptide transporter DtpA from E. coli in complex with valganciclovir provides insights into drug binding of human PepT1
.
J. Am. Chem. Soc.
141
,
2404
2412
32
Weitz
,
D.
,
Harder
,
D.
,
Casagrande
,
F.
,
Fotiadis
,
D.
,
Obrdlik
,
P.
,
Kelety
,
B.
et al (
2007
)
Functional and structural characterization of a prokaryotic peptide transporter with features similar to mammalian PEPT1
.
J. Biol. Chem.
282
,
2832
2839
33
Newstead
,
S.
(
2015
)
Molecular insights into proton coupled peptide transport in the PTR family of oligopeptide transporters
.
Biochim. Biophys. Acta
1850
,
488
499
34
Guettou
,
F.
,
Quistgaard
,
E.M.
,
Raba
,
M.
,
Moberg
,
P.
,
Low
,
C.
and
Nordlund
,
P.
(
2014
)
Selectivity mechanism of a bacterial homolog of the human drug-peptide transporters PepT1 and PepT2
.
Nat. Struct. Mol. Biol.
21
,
728
731
35
Schlessinger
,
A.
,
Welch
,
M.A.
,
van Vlijmen
,
H.
,
Korzekwa
,
K.
,
Swaan
,
P.W.
and
Matsson
,
P.
(
2018
)
Molecular modeling of drug-transporter interactions-an international transporter consortium perspective
.
Clin. Pharmacol. Ther.
104
,
818
835
36
Daniel
,
H.
,
Spanier
,
B.
,
Kottra
,
G.
and
Weitz
,
D.
(
2006
)
From bacteria to man: archaic proton-dependent peptide transporters at work
.
Physiology (Bethesda)
21
,
93
102
37
Steiner
,
H.-Y.
,
Naider
,
F.
and
Becker
,
J.M.
(
1995
)
The PTR family: a new group of peptide transporters
.
Mol. Microbiol.
16
,
825
834
38
Newstead
,
S.
(
2017
)
Recent advances in understanding proton coupled peptide transport via the POT family
.
Curr. Opin. Struct. Biol.
45
,
17
24
39
Law
,
C.J.
,
Maloney
,
P.C.
and
Wang
,
D.-N.
(
2008
)
Ins and outs of major facilitator superfamily antiporters
.
Ann. Rev. Microbiol.
62
,
289
305
40
Newstead
,
S.
,
Drew
,
D.
,
Cameron
,
A.D.
,
Postis
,
V.L.G.
,
Xia
,
X.
,
Fowler
,
P.W.
et al (
2011
)
Crystal structure of a prokaryotic homologue of the mammalian oligopeptide-proton symporters, PepT1 and PepT2
.
EMBO J.
30
,
417
426
41
Fowler
,
P.W.
,
Orwick-Rydmark
,
M.
,
Radestock
,
S.
,
Solcan
,
N.
,
Dijkman
,
P.M.
,
Lyons
,
J.A.
et al (
2015
)
Gating topology of the proton-coupled oligopeptide symporters
.
Structure
23
,
290
301
42
Parker
,
J.L.
,
Li
,
C.
,
Brinth
,
A.
,
Wang
,
Z.
,
Vogeley
,
L.
,
Solcan
,
N.
et al (
2017
)
Proton movement and coupling in the POT family of peptide transporters
.
Proc. Natl. Acad. Sci. U.S.A.
114
,
13182
13187
43
Solcan
,
N.
,
Kwok
,
J.
,
Fowler
,
P.W.
,
Cameron
,
A.D.
,
Drew
,
D.
,
Iwata
,
S.
et al (
2012
)
Alternating access mechanism in the POT family of oligopeptide transporters
.
EMBO J.
31
,
3411
3421
44
Jensen
,
J.M.
,
Ernst
,
H.A.
,
Wang
,
X.
,
Hald
,
H.
,
Ditta
,
A.C.
,
Ismat
,
F.
et al (
2011
)
Functional investigation of conserved membrane-embedded glutamate residues in the proton-coupled peptide transporter YjdL
.
Protein Pept. Lett.
19
,
282
287
45
Aduri
,
N.G.
,
Prabhala
,
B.K.
,
Ernst
,
H.A.
,
Jorgensen
,
F.S.
,
Olsen
,
L.
and
Mirza
,
O.
(
2015
)
Salt bridge swapping in the EXXERFXYY motif of proton-coupled oligopeptide transporters
.
J. Biol. Chem.
290
,
29931
29940
46
Daniel
,
H.
and
Kottra
,
G.
(
2004
)
The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology
.
Pflügers Arch.
447
,
610
618
47
Lyons
,
J.A.
,
Parker
,
J.L.
,
Solcan
,
N.
,
Brinth
,
A.
,
Li
,
D.
,
Shah
,
S.T.
et al (
2014
)
Structural basis for polyspecificity in the POT family of proton-coupled oligopeptide transporters
.
EMBO Rep.
15
,
886
893
48
Doki
,
S.
,
Kato
,
H.E.
,
Solcan
,
N.
,
Iwaki
,
M.
,
Koyama
,
M.
,
Hattori
,
M.
et al (
2013
)
Structural basis for dynamic mechanism of proton-coupled symport by the peptide transporter POT
.
Proc. Natl. Acad. Sci. U.S.A.
110
,
11343
11348
49
Martinez-Molledo
,
M.
,
Quistgaard
,
E.M.
,
Flayhan
,
A.
,
Pieprzyk
,
J.
and
Low
,
C.
(
2018
)
Multispecific substrate recognition in a proton-dependent oligopeptide transporter
.
Structure
26
,
467
476.e464
50
Minhas
,
G.S.
,
Bawdon
,
D.
,
Herman
,
R.
,
Rudden
,
M.
,
Stone
,
A.P.
,
James
,
A.G.
et al (
2018
)
Structural basis of malodour precursor transport in the human axilla
.
eLife
7
,
e34995
51
Samsudin
,
F.
,
Parker
,
J.L.
,
Sansom
,
M.S.
,
Newstead
,
S.
and
Fowler
,
P.W.
(
2016
)
Accurate prediction of ligand affinities for a proton-dependent oligopeptide transporter
.
Cell Chem. Biol.
23
,
299
309
52
Pieri
,
M.
,
Gan
,
C.
,
Bailey
,
P.
and
Meredith
,
D.
(
2009
)
The transmembrane tyrosines Y56, Y91 and Y167 play important roles in determining the affinity and transport rate of the rabbit proton-coupled peptide transporter PepT1
.
Int. J. Biochem. Cell Biol.
41
,
2204
2213
53
Jensen
,
J.M.
,
Ismat
,
F.
,
Szakonyi
,
G.
,
Rahman
,
M.
and
Mirza
,
O.
(
2012
)
Probing the putative active site of YjdL: an unusual proton-coupled oligopeptide transporter from E. coli
.
PLoS One
7
,
e47780
54
Birtalan
,
S.
,
Zhang
,
Y.
,
Fellouse
,
F.A.
,
Shao
,
L.
,
Schaefer
,
G.
and
Sidhu
,
S.S.
(
2008
)
The intrinsic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity of antibodies
.
J. Mol. Biol.
377
,
1518
1528
55
Meredith
,
D.
,
Temple
,
C.S.
,
Guha
,
N.
,
Sword
,
C.J.
,
Boyd
,
C.A.
,
Collier
,
I.D.
et al (
2000
)
Modified amino acids and peptides as substrates for the intestinal peptide transporter PepT1
.
Eur. J. Biochem.
267
,
3723
3728
56
Guettou
,
F.
et al (
2013
)
Structural insights into substrate recognition in proton-dependent oligopeptide transporters
.
EMBO reports
14
,
804
810
57
Nagamura
,
R.
et al (
2019
)
Structural basis for oligomerization of the prokaryotic peptide transporter PepTSo2
.
Acta Crystallogr. F Struct. Biol. Commun.
75
,
348
358
58
Huang
,
C.Y.
et al (
2015
)
In meso in situ serial X-ray crystallography of soluble and membrane proteins
.
Acta crystallographica. Section D, Biological crystallography
71
,
1238
1256
59
Huang
,
C.Y.
et al (
2016
)
In meso in situ serial X-ray crystallography of soluble and membrane proteins at cryogenic temperatures
.
Acta Crystallogr. D Struct. Biol.
72
,
93
112
60
Zhao
,
Y.
et al (
2014
)
Crystal structure of the E. coli peptide transporter YbgH
.
Structure
22
,
1152
1160
61
Boggavarapu
,
R.
,
Jeckelmann
,
J.M.
,
Harder
,
D.
,
Ucurum
,
Z.
and
Fotiadis
,
D.
(
2015
)
Role of electrostatic interactions for ligand recognition and specificity of peptide transporters
.
BMC Biol.
13
,
58
This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). Open access for this article was enabled by the participation of University of Oxford in an all-inclusive Read & Publish pilot with Portland Press and the Biochemical Society under a transformative agreement with JISC.